Pentara’s clients are primarily small pharmaceutical and biotech companies, but also include academic groups, medium and large pharmaceutical companies. Our projects include phase 1-phase 4 clinical trials. Our phase 1 experience includes single ascending dose (SAD), multiple ascending dose (MAD), pharmacokinetic, bioequivalence, and multi-stage cross-over trials. In phase 2, we provide a strategic balance between cost and sample size by helping our clients reduce error in order to increase the power of the study within a manageable budget. In many cases we can increase the impact of the sample size by 20-30%

Piechart of the percent categories of Pentara's clients

Representative clients:

  • Acumen Pharmaceuticals Inc.

  • Affiris AG

  • Alkahest

  • Allergan

  • Alzheon Inc.

  • Amylyx Pharmaceuticals Inc.

  • Apodemus

  • Avanir Pharmaceuticals, Inc.

  • Banner Alzheimer's Institute

  • Biogen

  • Dr. Richard Isaacson

  • Gerson Lehrman Group

  • Grifols Shared Services North America, Inc.

  • Ionis Pharmaceuticals, Inc.

  • Neurotrope BioScience, Inc.

  • Nutricia Research B.V.

  • PhotoPharmics, Inc.

  • Regenera Pharma LTD

  • Roche (F. Hoffmann-La Roche Ltd - Switzerland)

  • Spaulding Clinical Research

  • Toyama Chemical Co., LTD

  • vTv Therapeutics LLC